Comprehensive analysis of Aditya Birla SL Nifty Healthcare ETF (42361) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Aditya Birla Sun Life AMC Ltd
The investment objective of the scheme is to provide returns that before expenses, closely correspond to the total returns of securities as represented by Nifty Healthcare TRI, subject to tracking errors. However, the performance of scheme may differ from that of the underlying index due to tracking error. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.
A comprehensive at-a-glance view of key mutual fund health indicators
Strong Returns
High Risk
Low Expense Ratio
Equity Focused
Established Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Recent performance momentum
Market exposure level
Fund management costs
Outperformance vs benchmark
Historical performance consistency
Fund manager experience
Risk-adjusted returns
Assets under management
This fund has underperformed its benchmark by 0.26% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 18.73% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 18.51% |
| Max Healthcare Institute Ltd | Healthcare | 9.83% |
| Max Healthcare Institute Ltd | Healthcare | 9.32% |
| Divis Laboratories Ltd | Pharmaceuticals | 8.96% |
| Cipla Ltd | Pharmaceuticals | 8.80% |
| Cipla Ltd | Pharmaceuticals | 8.78% |
| Divis Laboratories Ltd | Pharmaceuticals | 8.43% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 8.10% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 7.78% |
Compare against ETFs Fund category average
This comparison shows how the fund performs relative to the ETFs Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in ETFs Fund category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| LIC MF Gold ETF | ₹8762.19 | 26.55% | 33.79% | 21.96% |
| Invesco India Gold ETF | ₹8510.17 | 27.09% | 34.60% | 21.81% |
| Invesco India Nifty 50 ETF | ₹2883.19 | 8.30% | 6.91% | 18.67% |
| Quantum Nifty 50 ETF | ₹2767.57 | 8.30% | 6.92% | 18.70% |
| BHARAT Bond ETF - April 2030 | ₹1523.90 | 5.56% | 10.42% | 8.86% |
| BHARAT Bond ETF - April 2031 | ₹1362.97 | 5.68% | 10.82% | 9.03% |
| BHARAT Bond ETF - April 2032 | ₹1280.95 | 5.49% | 10.71% | 9.26% |
| BHARAT Bond ETF - April 2033 | ₹1246.89 | 5.43% | 10.73% | N/A |
| DSP BSE Liquid Rate ETF | ₹1079.59 | 2.86% | 6.07% | N/A |
| Shriram Nifty 1D Rate Liquid ETF | ₹1059.74 | 2.80% | N/A | N/A |
A seasoned investment professional with over 4 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.